Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Somnomed Limited ( (AU:SOM) ) has issued an announcement.
SomnoMed Limited has announced the appointment of Andrew Price as a Director, effective January 17, 2025. Andrew Price, a seasoned executive with extensive experience in the medical device industry, previously served in various senior roles at ResMed. His expertise in supply chain management and global operations is expected to significantly benefit SomnoMed as it continues to expand its global presence.
More about Somnomed Limited
SomnoMed is a public company that specializes in providing treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. The company is recognized for its clinically proven medical oral appliance therapy, SomnoDent, which has been utilized by over 940,000 patients across more than 20 countries.
YTD Price Performance: 63.12%
Average Trading Volume: 4,787
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $63.55M
See more insights into SOM stock on TipRanks’ Stock Analysis page.
